Financial Survey: Acceleron Pharma (XLRN) vs. Its Peers

Acceleron Pharma (NASDAQ: XLRN) is one of 295 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its rivals? We will compare Acceleron Pharma to similar companies based on the strength of its risk, earnings, analyst recommendations, profitability, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Acceleron Pharma and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acceleron Pharma 1 5 11 0 2.59
Acceleron Pharma Competitors 765 3039 11207 227 2.72

Acceleron Pharma currently has a consensus price target of $43.67, suggesting a potential upside of 14.55%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 37.01%. Given Acceleron Pharma’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Acceleron Pharma has less favorable growth aspects than its rivals.

Volatility and Risk

Acceleron Pharma has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, Acceleron Pharma’s rivals have a beta of 6.66, suggesting that their average share price is 566% more volatile than the S&P 500.

Profitability

This table compares Acceleron Pharma and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acceleron Pharma -724.22% -44.67% -40.14%
Acceleron Pharma Competitors -5,509.84% -450.88% -42.12%

Institutional & Insider Ownership

77.4% of Acceleron Pharma shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 3.9% of Acceleron Pharma shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Acceleron Pharma and its rivals top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Acceleron Pharma $13.14 million -$96.08 million -15.31
Acceleron Pharma Competitors $260.16 million $66.28 million -6.28

Acceleron Pharma’s rivals have higher revenue and earnings than Acceleron Pharma. Acceleron Pharma is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Summary

Acceleron Pharma rivals beat Acceleron Pharma on 8 of the 12 factors compared.

Acceleron Pharma Company Profile

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

What are top analysts saying about Acceleron Pharma Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Acceleron Pharma Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit